OncoMatch/Clinical Trials/NCT06455410
GP Plus Adebrelimab Versus GP Neoadjuvant Chemotherapy for Nasopharyngeal Carcinoma
Is NCT06455410 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including GP and Adebrelimab for nasopharyngeal carcinoma.
Treatment: GP · Adebrelimab · concurrent chemoradiotherapy (CCRT) — The purpose of this study is to explore the efficacy and safety of neoadjuvant GP chemotherapy plus adebrelimab versus neoadjuvant GP chemotherapy in treating high-risk locoregionally advanced nasopharyngeal carcinoma patients.
Check if I qualifyExtracted eligibility criteria
Cancer type
Head and Neck Squamous Cell Carcinoma
Disease stage
Required: Stage T4N0-1M0, T1-4N2-3M0 (AJCC 8th)
Tumor staged as T4N0-1M0 or T1-4N2-3M0 (AJCC 8th)
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: radiation therapy
Prior therapy with radiation or systemic chemotherapy
Cannot have received: cytotoxic chemotherapy
Prior therapy with radiation or systemic chemotherapy
Cannot have received: immune checkpoint inhibitor (anti-PD-1, anti-PD-L1, anti-CTLA-4)
Prior exposure to immune checkpoint inhibitors,including anti-PD-1, anti- PD-L1, anti-CTLA-4 antibodies
Lab requirements
Blood counts
WBC ≥4.0×10^9 /L, Hemoglobin ≥ 90g/L, Platelet count ≥100×10^9/L
Kidney function
creatinine clearance rate ≥ 60 ml/min or Creatinine ≤ 1.5× upper limit of normal value
Liver function
ALT, AST, TBIL ≤2×upper limit of normal (ULN)
Adequate marrow function: White blood cell count (WBC)≥4.0×109 /L, Hemoglobin ≥ 90g/L, Platelet count ≥100×109/L. Alanine aminotransferase (ALT), aspartate aminotransferase (AST), serum total bilirubin (TBIL) ≤2×upper limit of normal (ULN). Adequate renal function: creatinine clearance rate ≥ 60 ml/min or Creatinine ≤ 1.5× upper limit of normal value.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify